{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Heffron SP"],"funding":["NHLBI NIH HHS"],"pagination":["1208-1213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9976777"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(8)"],"pubmed_abstract":["Aspirin's clinical efficacy may be influenced by body weight and mass. Although inadequate platelet inhibition by aspirin is suggested as responsible, evidence for this in non-diabetic patients is sparse. We investigated the influence of body weight and mass on aspirin's inhibition of platelet aggregation in healthy adults without diabetes. Cohort one (NYU, n = 84) had light transmission aggregometry (LTA) of platelet-rich plasma to submaximal adenosine diphosphate (ADP) and arachidonic acid (AA) before and following 1 week of daily 81 mg non-enteric coated aspirin. Subjects in the validation cohort (Duke, n = 66) were randomized to 81 mg or 325 mg non-enteric coated aspirin for 4 weeks, immediately followed by 4 weeks of the other dose, with LTA to submaximal collagen, ADP, and AA before "],"journal":["Platelets"],"pubmed_title":["Platelet inhibition by low-dose aspirin is not influenced by body mass or weight."],"pmcid":["PMC9976777"],"funding_grant_id":["R01 HL118049","R01 HL139909","R01 HL157430","R35 HL144993","R01 HL114978","K23 HL135398"],"pubmed_authors":["Windheim J","Barrett TJ","Voora D","Heffron SP","Berger JS"],"additional_accession":[]},"is_claimable":false,"name":"Platelet inhibition by low-dose aspirin is not influenced by body mass or weight.","description":"Aspirin's clinical efficacy may be influenced by body weight and mass. Although inadequate platelet inhibition by aspirin is suggested as responsible, evidence for this in non-diabetic patients is sparse. We investigated the influence of body weight and mass on aspirin's inhibition of platelet aggregation in healthy adults without diabetes. Cohort one (NYU, n = 84) had light transmission aggregometry (LTA) of platelet-rich plasma to submaximal adenosine diphosphate (ADP) and arachidonic acid (AA) before and following 1 week of daily 81 mg non-enteric coated aspirin. Subjects in the validation cohort (Duke, n = 66) were randomized to 81 mg or 325 mg non-enteric coated aspirin for 4 weeks, immediately followed by 4 weeks of the other dose, with LTA to submaximal collagen, ADP, and AA before ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-18T18:12:04.208Z","creation":"2025-04-07T05:47:19.09Z"},"accession":"S-EPMC9976777","cross_references":{"pubmed":["35768902"],"doi":["10.1080/09537104.2022.2087868"]}}